Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

The Dutch and Israeli company plans to take pridopidine into pivotal studies for Huntington’s, ALS

Serial entrepreneur Michael Hayden is taking the helm as CEO of Prilenia as it readies for a pair of studies next half that could show whether pridopidine can slow progression of neurodegenerative diseases more effectively than approved therapies.

The biotech raised $62.5 million in a Forbion-led series A on Wednesday, which will fund a Phase III trial in Huntington’s disease and a Phase IIb platform trial in amyotrophic lateral sclerosis.

Neither of the drugs approved for HD have an effect on functional capacity,

Read the full 829 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE